The Orals Plus Apidra and LANTUS (OPAL) study [17] evaluated treatment intensification in German patients with T2D not optimally controlled on insulin glargine plus OAMs by adding a single injection of rapid-acting insulin analogue glulisine before breakfast or the main mealtime. The gene discussed is INS; the disease is type 2 diabetes mellitus.